Abbott’s Machine Learning Algorithm Predicts Risk Of Heart Attacks In Trial
Results of a study in over 11,000 patients shows Abbott’s MI3 algorithm can risk-stratify patients with suspected myocardial infarction and help doctors decide which patients are most likely to benefit from earlier clinical decisions.
You may also be interested in...
The Israeli company raised $16m to support its Augmented Respiration Technology, a novel approach for delivering oxygen directly into the venous system. The company expects to earn FDA clearance for first product by 2023.
Abbott expects the ongoing recovery of medical procedure volumes to continue even as new virus variants are causing COVID-19 cases to increase in some geographies.
Johnson & Johnson’s medical device sales were up nearly 60% year-over-year in the second quarter of 2021 while Abbott reported 51% growth in its device business, reflecting the recovery in procedure volumes since the worst days of the pandemic in mid-2020.